Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) just unveiled an announcement.
Lepu Biopharma has convened its 2025 annual general meeting for May 19, 2026 in Beijing, where shareholders will review the board and supervisory reports, the group’s 2025 annual report and financial accounts, and approve the 2026 financial budget and 2025 profit distribution plan. Investors will also vote on reappointing Ernst & Young as auditor, appointing a new supervisor, changing the company’s registered address, amending the articles of association, and granting the board a general mandate to issue additional shares, signaling routine yet important decisions on governance, capital management, and corporate structure.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong that focuses on developing and commercializing innovative oncology therapies. The company operates through a group structure and is overseen by a board of directors and a board of supervisors, reflecting a typical governance framework for PRC-incorporated listed firms.
Average Trading Volume: 12,057,290
Technical Sentiment Signal: Hold
Current Market Cap: HK$10.16B
Find detailed analytics on 2157 stock on TipRanks’ Stock Analysis page.